Aridis Provides Corporate Update

LOS GATOS, Calif., March 30th, 2026 -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent developments.

Company update:
The Company maintained strong focus on realizing values on its three clinical assets AR-501, AR-301, and AR-320, while operating on a further reduced operational cash burn, which include continuing to delay the SEC filings and divesting the laboratory research facility. Further details are as follows:

Lead product candidate AR-301
In 4Q24, the Company received an investment proposal from a venture capital investment firm ('VC') in an amount that the Company believes is sufficient to complete the second and final Phase 3 study and product approval. The VC and the Company have been reaching out to other potential investors for the rest of the required capital. To date the majority of the capital investment goal has been committed, and the Company is in active discussions with prospective investors for the remaining investment commitment.

Phase 3 product candidate AR-320
The Company has recently filed a letter of legal complaint against AstraZeneca related to the termination of AR-320 product license. The complaint claims breach of contract related to the AR-320 (suvratoxumab) commercial license agreement, wrongful termination of the license agreement, wrongful misuse of Aridis's confidential information, and breach of the implied covenant of good faith and fair dealing.

Phase 2 product candidate AR-501
The Company executed an Asset Acquisition Terms Agreement in 4Q24 with an undisclosed pharmaceutical company to assign exclusive ownership of AR-501 upon receiving the Partner's payments totaling $6,500,000. However, the partner failed to follow through with its payment obligations in 2025 and the agreement has subsequently been terminated. The search for alternative pharmaceutical partners has been re-initiated. In parallel, the Company is also planning to file for non-dilutive grant funding.

Company operations and financials
The Company continued to be steadfast in our focus on procuring investments and business development discussions while further reducing operating expenses. Our goal is to service the

Streeterville loan and other debts that have accrued since the start of the COVID-19 pandemic, and to become current on its SEC filings as soon as revenues or additional funding are received.

About Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The Company has advanced the development of multiple clinical stage monoclonal antibodies (mAbs) targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with current standard-of-care broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The Company's mAb portfolio is complemented by a novel non-antibiotic small molecule anti-infective candidate mechanism being developed to treat lung infections in cystic fibrosis patients. The Company's pipeline is highlighted below:

Aridis' Pipeline

AR-301 (VAP). AR-301 is a fully human IgG1 mAb targeting gram-positive *Staphylococcus aureus* (*S. aureus)* alpha-toxin that has completed the first of two planned Phase 3 superiority clinical studies as an adjunctive treatment of *S. aureus* ventilator associated pneumonia (VAP).

AR-320 (VAP). AR-320 is a fully human IgG1 mAb targeting *S. aureus* alpha-toxin that has been evaluated in a Phase 3 clinical study as a preventative treatment of *S. aureus* colonized mechanically ventilated patients who do not yet have VAP.

AR-501 (cystic fibrosis). AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis (CF) patients. This program has successfully completed Phase 2a clinical development in CF patients.

AR-401 (blood stream infections). AR-401 is a fully human mAb preclinical program aimed at treating infections caused by gram-negative *Acinetobacter baumannii*.

AR-101 (HAP). AR-101 is a fully human immunoglobulin M, or IgM, mAb in Phase 2 clinical development targeting *Pseudomonas aeruginosa* (*P. aeruginosa)* liposaccharides serotype O11, which accounts for approximately 22% of all *P. aeruginosa* hospital acquired pneumonia (HAP) cases worldwide.

AR-201 (RSV infection). AR-201 is a fully human IgG1 mAb out-licensed preclinical program aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).

For additional information on Aridis Pharmaceuticals, please visit https://aridispharma.com/. [I haven't reviewed the website, but you'll want to be sure there are no inconsistencies with this release]

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Aridis' expectations, strategy, plans or intentions. These forward-looking

statements are based on Aridis' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the need for additional financing, the timing of regulatory submissions, Aridis' ability to obtain and maintain regulatory approval of its existing product candidates and any other product candidates it may develop, approvals for clinical trials may be delayed or withheld by regulatory agencies, risks relating to the timing and costs of clinical trials, risks associated with obtaining funding from third parties, management and employee operations and execution risks, loss of key personnel, competition, risks related to market acceptance of products, intellectual property risks, risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses, risks associated with the uncertainty of future financial results, Aridis' ability to attract collaborators and partners and risks associated with Aridis' reliance on third party organizations. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Aridis' 10-K for the year ended December 31, 2022 and Aridis' other filings made with the Securities and Exchange Commission. Forward-looking statements included herein are made as of the date hereof, and Aridis does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Contact:
Rebecca Edwards
Administrator
Aridis Pharmaceuticals, Inc.
info@aridispharma.com
408-385-1742

SOURCE Aridis Pharmaceuticals, Inc.